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Abstract 
Objective  
To describe the insights on the epidemiology of pain-structure association and the 
ramifications of these studies for clinical trials. 
Design  
Narrative review summarizing the pertinent literature in this area, summarizing some of the 
methodologic challenges inherent and proposing some research initiatives to further 
understanding of this complex science.  
Results 
The predominant symptom in most patients presenting with OA is pain. Over recent years a 
number of imaging based studies have narrowed the discord between structural findings on 
imaging and symptoms. The interpretation of pain in OA is still enigmatic and difficult to 
deal with both for clinicians and scientists. 
 
Conclusions 
We would envisage that over the next few years many of the pressing questions pertaining 
to research into the structure pain relationship will continue to be addressed. With this, we 
can expect clinically appropriate therapeutic advance. 
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Introduction 
Osteoarthritis (OA) is a highly prevalent and disabling disease that consequently has a 
formidable individual and societal impact. Approximately 10- 12% of the adult population 
have symptomatic OA (1;2). The risk of mobility disability (defined as needing help walking 
or climbing stairs) attributable to knee OA alone is greater than that due to any other 
medical condition in people aged 65 and over (3;4). Recent estimates suggest that 250 
million people worldwide are burdened by the presence of knee OA (5).  
This prevalent and disabling disease is heterogeneous and characterized by failure of the 
synovial joint organ (6). The disease occurs when the dynamic equilibrium between the 
breakdown and repair of joint tissues becomes unbalanced, often in a situation where the 
mechanical loads applied exceed those that can be tolerated by the joint tissues (7). OA is a 
heterogeneous disease that is characterized by progressive cartilage loss, subchondral bone 
remodelling, osteophyte formation, and synovial inflammation, with resultant joint pain and 
increasing disability. Whilst the progressive joint failure may cause pain and disability (4) 
approximately 50% of persons with structural changes consistent with OA are asymptomatic 
(8).  
In epidemiological investigation, OA is typically defined using conventional radiographs, and 
less frequently self-report (9). The reported prevalence of OA varies according to the 
method used to define the disease. The characteristic radiographic features used to define 
and classify OA severity are osteophytes (osteocartilaginous growths), subchondral sclerosis 
and joint space narrowing. Symptomatic OA in contrast requires the concomitant presence 
of pain (usually defined as pain on most days of the last month) and radiographic features. It 
is the presence of symptomatic OA that is important clinically, not simply the radiographic 
identification of an osteophyte or self-reported OA (where misclassification is even more 
problematic than the commonly used radiographic OA definition). 
The predominant symptom in most patients presenting with OA is pain. Over recent years a 
number of imaging based studies have narrowed the discord between structural findings on 
imaging and symptoms (10;11). This narrative review will summarize these findings and 
provide insights to the epidemiology of the pain-structure association and the ramifications 
of these studies for clinical trials especially pertaining to structure modification. We present 
here a narrative review, supported by a literature search up to January 2013 using Medline 
as a search engine. This is not a formal systematic review and prior reviews were referenced 
for their content. 
 
The determinants of pain 
The determinants of pain in OA are not well understood, but are believed to involve 
multiple interactive pathways that are best framed in a biopsychosocial framework (posits 
that biological, psychological and social factors all play a significant role in pain in OA) 
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(12;13) (Figure 1).  Psychosocial factors that can predispose to symptoms include self-
efficacy and pain catastrophizing, and the social context of arthritis (social support, pain 
communication) are all important considerations in understanding the pain experience. 
From a biological perspective, neuronal activity in nociceptive pathways is responsible for 
the generation of signals that ultimately are interpreted as joint pain. During inflammation 
or tissue (joint) injury, mediators are released into the joint that sensitize primary afferent 
nerves such that normally innocuous joint movements (such as increased physical activity, 
walking on high heeled shoes) may elicit a painful response. This is the neurophysiological 
basis of allodynia, i.e., the sensation of pain in response to a normally non-painful stimulus 
such as walking(14). Over time, this increased neuronal activity from the periphery 
(peripheral sensitization) can contribute to plasticity changes in the central nervous system 
(central sensitization)(15). In this instance, second order neurons in the spinal cord become 
more responsive to peripheral input, such as responding to lower-threshold stimuli that 
would not normally cause the neurons to fire, or an expansion of the receptive field of the 
dorsal horn neurons such that the transmission of nociceptive information to the 
somatosensory cortex is enhanced. Central sensitization can intensify the sensation of pain 
and even lead to pain responses from regions of the body remote from the inflamed joint, 
i.e., referred pain (14).  
Another important component of the biological contribution to pain comes from the 
multitude of tissues within the joint that contain nociceptive fibers and these are the likely 
sources of pain in osteoarthritis. The subchondral bone, periosteum, periarticular ligaments, 
periarticular muscle and joint capsule including its inner synovial lining are all richly 
innervated and are the likely source of nociception in OA. However, subjects with the same 
degree of structural damage experience widely different levels of pain, a phenomenon that is 
poorly understood (16).  
Research into pain is challenging as a result of the multiple risk factors responsible for pain 
occurrence and pain severity as well as pain being a subjective phenomenon. In population 
studies there is a significant discordance between radiographically diagnosed OA and knee 
pain (8). Whilst radiographic evidence of joint damage predisposes to joint pain, the 
underlying pathologies leading to pain cannot be readily discerned from radiography alone 
and may require consideration of other factors including function and load (17). Novel study 
designs are one approach to deal with the so-called structure-symptom discordance. For 
example, when inter-individual differences influencing the pain experience (e.g., genetics, 
psychosocial factors, etc.) are adequately accounted for, a strong relationship between 
radiographic OA and knee pain has been noted (18). In addition, it is important to consider 
that structural pathology is associated with somatosensory deficits in OA, since the extent of 
sensory loss directly correlated with the radiographic severity of knee OA, although causality 
has not been discerned (19). One study applying direct unanesthetized examination of 
articular tissues in the human knee joint has provided some insight into particular structures 
that do and do not elicit pain when probed (20). In lieu of such direct examination, utilizing 
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other imaging modalities such as magnetic resonance imaging (MRI), numerous structural 
alterations evident on MRI such as subchondral bone marrow lesions (21), subarticular bone 
attrition (22), synovitis and effusion (23;24) have been related to knee pain. Furthermore, 
changes in BMLs and synovitis on MRI are associated with fluctuations in knee pain in 
patients with knee OA (25). These findings were systematically reviewed within the last 2 
years (26). Twenty-one studies examined the concurrent relation of MRI findings in OA to 
symptoms (26). Of these, just over half (13 studies) demonstrated a statistically significant 
association, defined as P <0.05, indicating that studies to date have found inconsistent 
associations of structural features to symptoms. Nonetheless, in general, large bone marrow 
lesions were strongly associated with knee pain, followed by synovitis and effusion, and 
cartilage volume/ thickness. There was no consistent relation of meniscal tears to the 
presence of pain. Interpretation of these relationships must be made cautiously as it is not 
clear as to whether all of these associations are truly causal, or rather are markers of the 
severity of other structural pathology that may be contributing to the pain experience. 
 
Table 1. OA structure pain correlation studies 
 Number of supportive studies (references) 
Structural feature Supportive of association  Negative or neutral findings 
Bone marrow lesions 5 (22;27-30) 2 (31;32) 
Synovitis 3 (22;23;33) 2 (34;35) 
Effusion 3 (23;27;32)  
Cartilage 3 (29;31;36) 1 (32) 
Meniscus  1 (22) 4 (31;32;37;38) 
Bone attrition 1 (22)  
Osteophytes 1 (32) 1 (22) 
Peri-articular lesions 1 (39) 1 (32) 
 
The different tissues within the joint and their respective contribution to symptoms are 
discussed further below.  
Hyaline articular cartilage 
Articular cartilage is both aneural and avascular. As such, cartilage is incapable of directly 
generating pain, inflammation, stiffness, or any of the symptoms that patients with OA 
typically describe, (40) at least early on in the disease course prior to potential 
neurovascular invasion that may occur in late or end-stage disease (41). During cartilage 
degradation, substances are released that are capable of inducing inflammation in the joint. 
Some studies have suggested a relation between cartilage morphometry and lesions and the 
symptoms of OA (42). It is important to note that this disease of the whole joint 
concurrently affects other tissues that do contain nociceptors. The studies that have 
demonstrated a relation of cartilage damage to pain have traditionally investigated the role 
of cartilage in predisposing to symptoms in isolation from other tissues and as such cannot 
provide insight into the independent contribution of cartilage pathology to pain. A recent 
study suggested that areas of denuded cartilage are related to symptoms (43). Again, the 
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likely mechanism for symptom genesis is through secondary mechanisms such as: 1) 
exposing the underlying subchondral bone and the inherent symptom genesis (such as 
exposure of nociceptors) from this structural alteration; (2) vascular congestion of 
subchondral bone leading to increased intraosseous pressure; (3) synovitis secondary to 
articular cartilage damage with activation of synovial membrane nociceptors. That is, knees 
exhibiting denuded areas of cartilage are more likely to have concomitant potentially painful 
tissue pathology such as synovitis/effusion and BMLs. 
Subchondral bone 
Periarticular bone changes associated with OA can be segregated into distinct patterns 
based on the anatomic location and pathogenic mechanisms.  These alterations include 
progressive increase in subchondral plate thickness, alterations in the architecture of 
subchondral trabecular bone, formation of new bone at the joint margins (osteophytes), 
development of subchondral bone cysts and advancement of the tidemark associated with 
vascular invasion of the calcified cartilage.  
The osseous changes with the most supportive evidence for a role in symptom genesis are 
the so-called “bone marrow lesions” (Figure 2). These biomechanically induced lesions in 
the bone marrow reflecting the histologic changes of fibrosis, trabecular microfractures and 
other manifestations of bone remodelling play an integral if not pivotal role in the 
symptoms that emanate from knee OA and its structural progression (28;44). More recently 
their relation to pain severity (45) and incident pain (46) was also demonstrated. There is 
conflicting data, albeit from smaller studies with different methods, suggesting no relation 
of bone marrow lesions to pain (31;32); however the balance of data would support a strong 
relation of bone marrow lesions to pain (26;47). 
Other bone-related causes of pain include periostitis associated with osteophyte formation 
(48), subchondral microfractures (49), bone attrition (22) and bone angina due to decreased 
blood flow and elevated intraosseous pressure (50), which are reflected on imaging as bone 
marrow lesions. Given the strong relationship between bony structural changes, symptoms 
and structural progression targeting these more selectively would be a major advance in 
delineating appropriate therapies.   
Synovitis, effusion 
The synovial reaction in OA includes synovial hyperplasia, fibrosis, thickening of synovial 
capsule, activated synoviocytes and in some cases lymphocytic infiltrate (B- and T-cells as 
well as plasma cells) (51). Synovial causes of pain include irritation of sensory nerve endings 
within the synovium from osteophytes and synovial inflammation that is due, at least in part, 
to the release of prostaglandins, leukotrienes, proteinases, neuropeptides and cytokines 
(13;52).  
Synovitis and effusion is frequently present in osteoarthritis and correlates with pain and 
other clinical outcomes (23;27;33). A semi-quantitative measure of synovitis from the 
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infrapatellar fat pad is associated with pain severity and similarly change in synovitis is 
associated with change in pain severity (24;26;47) and pain fluctuation (25). 
In an important caveat to this analysis a recent study compared non-enhanced proton-
density-weighted fat-suppressed (PDFS) sequences with T1-weighted (T1w) fat-suppressed 
(FS) contrast-enhanced (CE) sequences for semi-quantitative assessment of peripatellar 
synovitis in OA (53). These data suggested that signal alterations in Hoffa’s fat pad on non-
enhanced images do not always represent synovitis as seen on T1w CE images but are a 
rather non-specific albeit sensitive finding (Figure 3).  
Meniscus 
An intact and functional meniscus is important to the preservation of joint integrity and 
prevention of further joint damage. In contrast, the meniscus plays a much smaller role in 
symptom genesis. There is some emerging data that incident tears and those involving the 
red zone (outer rim) of the meniscus may play a limited role in symptom genesis through 
angiogenesis and associated sensory nerve growth (54). However in clinical practice an 
unfortunate consequence of the frequent use of MRI in clinical practice is the frequent 
detection of meniscal tears (55). Degenerative lesions, described as horizontal cleavages, 
flap (oblique), or complex tears or meniscal maceration or destruction are associated with 
older age and are almost universal in persons with osteoarthritis (55). In asymptomatic 
subjects with a mean age of 65 years, a tear was found in 67% using MRI, whereas in 
patients with symptomatic knee OA, a meniscal tear was found in 91% (56).  In the interests 
of preserving menisci an important cautionary note: meniscal tears are nearly universal in 
persons with knee OA and are unlikely to be a cause of increased symptoms (56;57). The 
penchant to remove menisci is to be avoided, unless there are symptoms of locking or 
extension blockade, at which point surgical treatment often becomes necessary (58).  
The role of other tissues 
Periarticular muscles influence joint loading, and impairments in muscle function have been 
observed in people with OA (59). Various studies have investigated the role of muscle 
strength on joint integrity and some have explored the impact on physical functioning. 
Sharma et al (60) conducted a three-year longitudinal cohort study investigating factors 
contributing to poor physical functioning in 257 patients with knee OA. They found that in 
addition to factors such as age, reduced absolute quadriceps and hamstrings strength and 
poor proprioceptive acuity increased the likelihood of poor physical functioning as 
measured by the time to perform five repetitions of rising and sitting in a chair. In addition 
to their exploration in observational studies there is ample evidence from clinical trials 
demonstrating that muscle strengthening exercises result in improvements in pain, physical 
function and quality of life in people with knee OA (61;62). 
 
Epidemiologic insights- Challenges in studying structure-pain relationships 
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This section will address some of the important epidemiologic challenges and the insights 
that have come from imaging on structure-symptom relationships. To date, little is known 
about the natural history of structural lesions and the clinical signs and symptoms in the 
development of OA. This makes studying the independent effect of each specific structural 
lesion on the occurrence of clinical symptoms, such as pain or functional limitations, 
challenging.  
This is especially the case as MRI technology has been more widely used to identify various 
pathologic changes in the joint. There is a tendency to include all structural lesions in the 
same statistical model to obtain “independent” associations of various structural lesions and 
risk of the outcome, such as pain, and to compare the magnitudes of effect of each 
structural lesion on the outcome of interest.  Without knowing the causal pathway and 
chronology of occurrence of these lesions, standard approaches of automatically mutually 
adjusting for all factors can not only lead to biased effect estimates (due to selection bias 
(63)), but the effect estimates for each of the structural lesions are not directly comparable 
with one another. (64;65). Thus, without improved understanding of the basic pathogenesis 
of such lesions and more appropriate statistical methods, even with improvements in the 
quality of image assessment, such approaches will unfortunately be unable to provide valid 
insights. For example, if one is interested in assessment of the relation of meniscal extrusion 
and bone marrow lesions to the risk of frequent knee pain, and assuming meniscal extrusion 
often occurs before BML, any attempt to compare the magnitude of effect of each 
structural lesion generated from the same regression model is problematic.. First, the effect 
estimate for BML reflects its total effect on risk of frequent knee pain (i.e., all possible 
means by which BMLs may exert their effects), but the effect estimate for meniscal 
extrusion represents its direct effect on pain through pathways other than through BMLs. 
These two effect estimates are not directly comparable.  Second, the direct effect of 
meniscal extrusion may be biased owing to selection bias (i.e., collider-stratification bias) 
unless appropriate analysis methods are used (66;67). 
 
At present we do not know how much of the variance in pain is accounted for by structural 
change and in addition, assessing the causal contributions of the various pathologic features 
in OA to the pain experience has been, and remains difficult. One reason for this difficulty is 
that the general approach to studying the pathologic features in OA occurs late in the 
disease process when numerous pathologic changes are already commonly present. In fact, 
abnormalities on MRI are common even in knees that are considered to be radiographically 
“normal” (Kellgren and Lawrence (KL) grade 0). For example, using data from a population-
based sample of adults aged 50 and over unselected for knee pain or knee OA, 89% of knees 
that were KL=0 had at least one type of abnormality, with the three most common findings 
being osteophytes (74%), cartilage damage (69%), and bone marrow lesions (52%), and MRI-
detected abnormalities were equally highly prevalent in both those with (91%) and without 
(88%) knee pain (68).  
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Another reason for difficulty in discerning the relation of pathologic OA features to pain is 
because other potential confounders are often not adequately accounted for in 
observational studies. As discussed above, a number of factors, including genetics, 
sensitization, mood, coping, catastrophizing, and the social context, among others, influence 
the pain experience. Unless such factors are appropriately controlled for, the true 
magnitude of effect of structural pathology on pain cannot be validly determined. Using a 
within-person knee-matched approach to control for such between-person differences, 
radiographic severity has been demonstrated to have a strong dose-response relationship 
with presence of pain, pain severity, and incident (new onset) pain (18). Using a different 
within-person knee-matched approach, Zhang et al. demonstrated the relationship of 
changes in bone marrow lesions and in synovitis/effusion with changes in pain presence and 
severity (25), demonstrating that fluctuation in pain can be linked to fluctuation in structural 
pathology. More specifically, changes in BML and synovitis were both associated with knee 
pain fluctuation and pain severity (25). 
 
Insights for intervention studies  
Unfortunately at present there is no OA equivalent to measuring high lipid levels, 
atherosclerosis, hypertension, or high glucose and glucose tolerance, for example, as we 
have for cardiovascular disease and diabetes, where one can detect and treat the disease 
precursors pre-emptively before the associated processes lead to end-organ failure. In 
addition in OA, even if we had such a biomarker, there are no therapies proven to reduce 
the risk of progression to OA. Instead, the “watchful waiting” of steady decline to end-stage 
joint disease is a major cause of disablement and loss of quality of life (10). 
Recent advances in other prevalent rheumatic diseases has resulted in diseases that were 
associated with inexorable decline, be treated proactively with associated preservation of 
structure and function. The advance of biologic therapy in rheumatoid arthritis has seen 
dramatic shifts in preservation of structure and discussion of a new classification of disease 
remission. Recent evolution in medical care for osteoporosis has seen a marked reduction in 
fracture rates with their associated morbidity, with the appropriate institution of anti-
resorptive therapy. Unfortunately, we don’t have this proactive stance available in OA, and 
with current structural definitions and measurement strategies that is unlikely to change. 
We need to focus on earlier disease where changes may be reversible (Figure 4), if we are 
not to continue current therapeutic approaches that are largely palliative. 
A number of obstacles exist to revising the status of OA care, amongst these is our penchant 
to utilize radiography to diagnose and study OA (69). This penchant is reinforced by the 
regulatory hurdles that have led to promulgation of a suboptimal imaging modality in OA 
studies. Utilizing radiography as a means of defining disease serves to limit itself to a disease 
window that evaluates only some of the synovial joint features affected by OA, and this 
evaluation may reflect only the later stages of disease evolution. Other technologies such as 
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magnetic resonance imaging (MRI) may be more sensitive to early pathologic changes (70). 
Efforts to modify the course of the disease may not be successful if we focus on late disease 
when the mechanical derangements overwhelm any reparative potential (71). It is akin to 
studying and intervening upon an end-stage organ. If non-surgical interventions as a single 
therapy are to be trialled effectively, selecting those with earlier disease, prior to the 
development of marked aberrant mechanics, is a preferable solution. In the recent iNOS 
trial (72) there may have been an effect in KL=2 knees, supporting the perspective about 
needing to intervene earlier when biomechanical effects may not be as difficult to 
overcome. The fact that the effects were lost over the longer term suggests that perhaps 
targeting a single pathway even in milder disease may be insufficient. 
The denudation of hyaline cartilage (subchondral bone exposed) is not reversible and by the 
time persons develop radiographic OA, the overwhelming majority of persons have areas of 
denuded cartilage (73). MRI studies provide strong evidence that ascertainment of disease 
on radiographs only provides insights into late stage disease (74;75). Further we need to 
identify and target the tissue that leads to the cascade of events we describe as joint failure. 
Preclinical studies with varying levels of efficacy suggest that a wide array of agents 
including glucosamine sulfate, chondroitin sulfate, sodium hyaluronan, doxycycline, MMP 
inhibitors, bisphosphonates, calcitonin, diacerein and avocado-soybean unsaponifiables can 
modify disease progression (76).  At this point however there is no pharmacologic agent 
that has been approved by regulatory authorities for disease modification in OA. It may be a 
while before a disease-modifying drug is available as current trial strategies remain 
neglectful of some simple fundamentals and or hampered by outdated regulatory 
requirements. Our current paradigm of studying persons with end-stage irreversible disease 
needs to change if we are to identify a stage of the disease where the structural changes 
may be reversible. There are promising therapies being developed for new OA targets for 
both symptoms and structure, but we need to pay heed to the lessons we have learned and 
consider the obstacles to development if they are to be effective (77). 
Given the bulk of the evidence supporting an important relation of synovitis/effusion and 
bone marrow lesions to pain in OA, these appear, at present, to be the most promising 
targets for symptom modification. Intra-articular glucocorticoid injections, which 
presumably target inflammation related to synovitis/effusion, have been demonstrated to 
be superior to placebo in the short-term, but long-term benefits have not been found (78). 
Nonetheless, because of the important role inflammatory mediators play in sensitization of 
nociceptors and therefore contribute to the pain experience, appropriate targeting of 
inflammatory cytokines (e.g., TNF-α, IL-1β) would be theoretically expected to modulate 
symptoms.   
A recent randomized trial of intravenous zoledronic acid vs. placebo demonstrated 
significant bone marrow lesion area reduction as well as pain reduction at 6 months, 
suggesting the possibility of symptom modification by targeting of bone marrow lesions 
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(79). Similar promising findings have also occurred for strontium ranelate and calcitonin. 
However, since OA is a multifactorial disease, targeting single lesions may not be successful 
unless other factors are also addressed (e.g., abnormal biomechanics) and/or intervention 
occurs early in the process when a particular pathway (e.g., inflammation) may be the 
predominant driving mechanism. The challenge lies in identifying that point in the 
preclinical disease state for early intervention prior to a multitude of pathologic pathways 
working in concert leading to end-stage disease. 
Further, it is possible that structure modification itself would not necessarily have major or 
beneficial effects on symptoms. First, positive symptom effects may not be detectable in the 
time-frame that is typically feasible for the conduct of randomized trials if structure 
modification may lead to prevention of symptoms only in the long-term. Second, while 
structural pathology in the joint undoubtedly contributes to pain in OA, as discussed above, 
other factors also contribute to the pain experience. As an extreme example, approximately 
20-30% of patients report poor long-term pain outcomes post-knee replacement, which is 
presumably a definitive means of structure modification (80).  Third, we must bear in mind 
that nociception plays an important protective role, and therefore complete ablation of 
nociception should not be a therapeutic goal.  
Other imaging modalities may also facilitate insights into the relation of structure to 
symptoms (81). For example, functional MR imaging has shown early promise in depicting 
the central alterations consistent with the pain experience.  
Research opportunities 
Because the experience of pain in OA differs between individuals for the same degree of 
joint pathology, additional research efforts are needed beyond solely structure modification 
for a more comprehensive approach to symptom modification in OA. Means of addressing 
poor coping skills and catastrophizing exist through cognitive behavioural therapy, but are 
under-recognized issues and such therapies are underutilized.  Research focusing on 
addressing these important aspects of the pain experience would improve pain 
management in OA.  
Insights into specific factors leading to peripheral and central sensitization in OA would 
provide opportunities for therapeutic targeting to reduce pain and potentially reduce the 
transition from acute to chronic pain. For example, the relation of joint structural alterations 
to peripheral sensitization remains unexamined. The transition from acute, activity-related 
pain to chronic, persistent pain is not well-understood, and is the source of most of the 
morbidity related to OA. If targeting inflammation, for example, prevents sensitization and 
transition to chronic persistent pain, it would have tremendous public health impact.  It is 
possible that one of the reasons for the success of TNF-α agents in rheumatoid arthritis is 
not just the effects on synovial inflammation, but also on sensitization as pain is so markedly 
improved (82). Because pain sensitization is likely an important component of the pain 
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experience in OA, further development and testing of centrally-acting agents that may 
specifically target pain mechanisms at play in OA is warranted. Management of OA pain 
ideally needs to shift to a mechanism-based approach for more optimal symptom 
modification. Structural modification alone is likely to be insufficient in bringing about 
adequate and comprehensive pain management in this complex disease. 
As discussed previously, at present we still do not have a clear understanding of how 
common are the various structural changes and how they account for the community 
prevalence of knee pain. Similarly the variance of pain explained both by independent 
structural changes (e.g., BMLs vs. synovitis vs. effusion) as well as their sum total remain 
poorly defined.  
 
Conclusion 
There are many challenges in the assessment of pain etiology as well as methodological 
hurdles to overcome. Nevertheless, in recent years many insights have been gleaned which 
has narrowed what was previously a large discord between structural change and the 
symptom experience. We would envisage that this gap will continue to narrow as we pay 
greater heed to some of the methodologic challenges highlighted in this review. With 
greater understanding we can anticipate that this will lead to therapeutic breakthroughs by 
virtue of targeting therapies towards lesions earlier in the disease cascade and more closely 
linked to the symptom experience and future structural progression. 
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Legends to Figures: 
Figure 1. Biospsychosocial model depicting the relation of structural pathology to the 
experience of pain 
 
Figure 2: 
   
2a    2b    2c 
Anteroposterior knee x-ray (1a) shows mild medial tibiofemoral joint space narrowing, tibial 
and femoral osteophytes (arrowheads) and faint calcifications of both medial and lateral 
menisci (arrows) in keeping with meniscocalcinosis. Coronal proton density-weighted fat-
suppressed MRI (1b) confirms the tibial and femoral ospteophytes (arrowheads) and 
demonstrates an extensive loss of medial tibial femoral cartilage with denuded bone 
contrasting with mild medial tibiofemoral joint space narrowing on x-ray. The MRI also 
discloses large subchondral medial tibial and femoral bone marrow lesions (thick arrows) 
and moderate size tibial subspinous bone marrow lesion at the ACL insertion (thin arrows). 
The medial meniscus is partially macerated and extruded. Coronal proton density-weighted 
MRI (1c) shows a posterior root tear of the medial meniscus (arrow). 
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Figure. 3: 
  
3a       3b 
Axial proton density-weighted fat-suppressed MRI (2a) shows homogeneous moderate size 
knee joint effusion (arrow). The axial T1-weighted contrast-enhanced fat-suppressed MRI 
(2b) differentiates between the true joint effusion which does not enhance after contrast 
administration (arrow) and true synovitis which does show enhancement after contrast 
administration (arrowheads).  
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Figure 4. The natural history of osteoarthritis and the purported roles of biomarkers during the disease process. Original attributed to V 
Kraus (originally presented at OARSI Congress 2009: Kraus, VB. 2009. Clinical perspective on the role of biomarkers and the diagnosis and 
monitoring of OA. Osteoarthritis Cartilage Sept 17 (Suppl 1): S1.) can also be found in (83).  
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